The interferon regulatory factor 1 (IRF1) antibody is a key tool for studying the role of IRF1. a transcription factor critical in immune regulation and cellular stress responses. IRF1. a member of the IRF family, is activated by interferons (IFNs), cytokines, and pathogens, and functions as a mediator of innate and adaptive immunity. It binds to interferon-stimulated response elements (ISREs) in promoter regions to regulate genes involved in MHC class I antigen presentation, antiviral defense, apoptosis, and tumor suppression. IRF1 also interacts with signaling pathways like JAK-STAT and NF-κB, modulating inflammatory responses and cell cycle control. Dysregulation of IRF1 is linked to autoimmune diseases, cancer progression, and viral evasion mechanisms.
IRF1 antibodies are widely used in techniques such as Western blotting, immunohistochemistry, and chromatin immunoprecipitation (ChIP) to evaluate IRF1 expression, localization, and DNA-binding activity. These antibodies help characterize IRF1's role in immune cell differentiation, tumor microenvironment modulation, and host-pathogen interactions. Specific clones (e.g., D5E4. EP1558Y) and host species (rabbit, mouse) are validated for sensitivity and specificity, often using IRF1-knockout controls. Researchers employ IRF1 antibodies to explore its dual role as a tumor suppressor or oncogene, depending on cellular context, and its potential as a therapeutic target or diagnostic biomarker in diseases like leukemia, chronic inflammation, and viral infections.